[HTML][HTML] Long COVID and its Management
HC Koc, J Xiao, W Liu, Y Li, G Chen - International journal of …, 2022 - ncbi.nlm.nih.gov
The pandemic of COVID-19 is the biggest public health crisis in 21 st Century. Besides the
acute symptoms after infection, patients and society are also being challenged by the long …
acute symptoms after infection, patients and society are also being challenged by the long …
[HTML][HTML] Cytokine storm in COVID-19: the current evidence and treatment strategies
Y Tang, J Liu, D Zhang, Z Xu, J Ji, C Wen - Frontiers in immunology, 2020 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is the pathogen that causes
coronavirus disease 2019 (COVID-19). As of 25 May 2020, the outbreak of COVID-19 has …
coronavirus disease 2019 (COVID-19). As of 25 May 2020, the outbreak of COVID-19 has …
Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
COVID-19: Immunology and treatment options
S Felsenstein, JA Herbert, PS McNamara… - Clinical …, 2020 - Elsevier
The novel coronavirus SARS-CoV2 causes COVID-19, a pandemic threatening millions. As
protective immunity does not exist in humans and the virus is capable of escaping innate …
protective immunity does not exist in humans and the virus is capable of escaping innate …
Candidate drugs against SARS-CoV-2 and COVID-19
DL McKee, A Sternberg, U Stange, S Laufer… - Pharmacological …, 2020 - Elsevier
Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global
health for the future. Because a vaccine against the virus will not be available in the near …
health for the future. Because a vaccine against the virus will not be available in the near …
COVID-19: A review of therapeutic strategies and vaccine candidates
The world is engulfed by one of the most widespread and significant public health crises in
decades as COVID-19 has become among the leading causes of death internationally. The …
decades as COVID-19 has become among the leading causes of death internationally. The …
[HTML][HTML] Pharmaco-immunomodulatory therapy in COVID-19
The severe acute respiratory syndrome coronavirus 2 associated coronavirus disease 2019
(COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory …
(COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory …
[HTML][HTML] Natural history of COVID-19 and current knowledge on treatment therapeutic options
WG Dos Santos - Biomedicine & Pharmacotherapy, 2020 - Elsevier
Despite intense research there is currently no effective vaccine available against the new
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in the later 2019 …
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in the later 2019 …
Hydroxychloroquine for early treatment of adults with mild coronavirus disease 2019: a randomized, controlled trial
O Mitjà, M Corbacho-Monné, M Ubals… - Clinical Infectious …, 2021 - academic.oup.com
Background No effective treatments for coronavirus disease 2019 (COVID-19) exist. We
aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be …
aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be …
Host–microbiota interactions in immune-mediated diseases
WE Ruff, TM Greiling, MA Kriegel - Nature Reviews Microbiology, 2020 - nature.com
Host–microbiota interactions are fundamental for the development of the immune system.
Drastic changes in modern environments and lifestyles have led to an imbalance of this …
Drastic changes in modern environments and lifestyles have led to an imbalance of this …